zika
viru
zikv
reemerg
pose
signific
health
threat
especi
due
risk
fetal
develop
necessit
safe
effect
vaccin
protect
pregnant
women
zika
envelop
domain
iii
identifi
safe
effect
vaccin
candid
howev
poorli
immunogen
previous
show
plantmad
recombin
immun
complex
ric
vaccin
robust
platform
improv
immunogen
weak
antigen
studi
alter
antigen
fusion
site
ric
platform
accommod
ntermin
fusion
igg
heavi
chain
nric
thu
wider
rang
antigen
result
improv
ric
express
normal
ctermin
fusion
cric
type
ric
contain
effici
assembl
plant
purifi
homogen
simpl
onestep
purif
ric
strongli
bound
complement
receptor
elicit
strong
antibodi
titer
correl
zikv
neutral
either
nric
cric
codeliv
plantproduc
hepat
b
core
hbc
viruslik
particl
vlp
display
combin
elicit
greater
antibodi
titer
strongli
neutral
zikv
either
ric
vlp
alon
two
dose
without
adjuv
find
demonstr
antigen
requir
free
nterminu
optim
antigen
display
use
ric
system
plantmad
ric
vlp
highli
effect
vaccin
target
thu
ric
platform
gener
appli
wider
varieti
antigen
zika
viru
zikv
consid
global
public
health
threat
due
factor
involv
spread
involv
neonat
complic
zika
viral
transmiss
report
countri
worldwid
februari
world
health
organ
declar
public
health
emerg
intern
concern
respons
grow
number
global
zika
infect
increas
amount
evid
suggest
link
zika
infect
congenitalneurolog
complic
guillainbarr
syndrom
neonat
microcephali
sinc
signific
interest
develop
vaccin
therapeut
aid
zikv
time
vaccin
candid
test
nonclin
studi
vaccin
candid
advanc
past
anim
preclin
studi
sever
phase
human
clinic
trial
least
one
phase
ii
clinic
trial
zika
viru
zikv
positivesens
singlestrand
rna
viru
member
genu
flaviviru
current
genu
flaviviru
consist
fiftythre
document
speci
along
grow
number
tent
speci
virus
produc
singl
polyprotein
process
produc
three
structur
protein
c
prm
e
seven
nonstructur
protein
prm
precursor
transmembran
protein
proteolyt
cleav
virion
matur
host
cell
proteas
produc
matur
membran
protein
matur
viru
particl
copi
envelop
glycoprotein
e
membran
protein
arrang
icosahedr
structur
e
dimer
structur
cover
viral
surfac
mediat
bind
entri
host
cell
main
antigen
determin
viru
envelop
glycoprotein
e
sinc
display
surfac
matur
viru
particl
target
number
neutral
antibodi
neutral
antibodi
gener
approv
vaccin
yellow
fever
viru
japanes
enceph
viru
tickborn
enceph
viru
close
relat
zikv
appear
correl
viral
protect
reason
mani
vaccin
candid
focu
produc
neutral
antibodi
target
zikv
e
protein
one
exampl
experiment
dna
vaccin
candid
current
phase
ii
clinic
trial
candid
encod
zikv
wild
type
precursor
transmembran
prm
envelop
e
protein
howev
dna
vaccin
licens
human
use
may
risk
chromosom
integr
via
nonhomolog
recombin
import
issu
must
circumv
potenti
danger
flaviviru
vaccin
provok
antibodydepend
enhanc
ade
ade
occur
nonneutr
antibodi
develop
respons
one
viral
infect
vaccin
crossreact
form
complex
anoth
viru
upon
infect
complex
bind
cell
fcc
complementassoci
receptor
taken
myeloid
cell
howev
sinc
antibodi
neutral
viru
sever
viral
infect
enhanc
antibodi
direct
zika
fusion
loop
e
protein
enhanc
dengu
viru
infect
antibodi
direct
e
domain
iii
elicit
neutral
typespecif
antibodi
caus
ade
howev
poorli
immunogen
necessit
strategi
improv
immunogen
immun
complex
defin
antibodi
bound
cognat
antigen
long
known
enhanc
immun
respons
anim
model
howev
simpli
mix
antibodi
antigen
often
produc
inconsist
result
monomer
antibodybound
antigen
unabl
effici
crosslink
immun
receptor
circumv
problem
recombin
immun
complex
ric
consist
antibodi
fuse
cognat
antigen
also
explor
vaccin
platform
due
abil
form
larg
antigenantibodi
complex
mimic
found
natur
infect
complex
format
result
number
benefit
includ
direct
activ
antigen
present
cell
via
crosslink
fcc
receptor
enhanc
antigen
present
bcell
effect
stimul
immun
respons
high
avid
bind
increas
tcell
activ
develop
univers
ric
platform
provid
conveni
way
produc
immun
complex
format
without
need
find
specif
antibodyantigen
pair
studi
versatil
ric
platform
improv
optim
design
ric
plant
express
vector
lead
enhanc
stabil
express
ric
show
properli
assembl
plantmad
ric
viruslik
particl
vlp
contain
antigen
highli
immunogen
mice
produc
robust
antibodi
titer
capabl
effici
neutral
zikv
absenc
adjuv
furthermor
vlp
ric
codeliv
synergist
enhanc
antibodi
titer
zikv
neutral
demonstr
detail
construct
vector
use
studi
avail
supplement
materi
beydv
plant
express
vector
construct
introduc
agrobacterium
tumefacien
via
electropor
result
strain
verifi
restrict
digest
pcr
grown
overnight
use
infiltr
leav
n
benthamiana
maintain
ric
vector
express
heavi
chain
light
chain
agroinfiltr
n
benthamiana
leav
vector
similar
previous
describ
zikv
e
domain
iii
antigen
instead
denv
antigen
transgen
n
benthamiana
plant
silenc
xylosyltransferas
fucosyltransferas
enzym
use
sinc
plant
produc
highli
homogen
humanlik
glycosyl
pattern
improv
vivo
fc
receptor
bind
briefli
bacteria
pellet
centrifug
min
resuspend
infiltr
buffer
mm
nmorpholino
ethanesulfon
acid
me
ph
mm
unless
otherwis
describ
result
bacteri
suspens
inject
use
syring
without
needl
leav
small
punctur
plant
tissu
harvest
day
postinfiltr
dpi
state
experi
gfp
sampl
leav
visual
uv
illumin
use
lamp
uvp
upland
ca
usa
ric
vlp
leaf
sampl
homogen
icecold
wv
extract
buffer
ph
mm
trishcl
mm
nacl
mm
edta
triton
mm
sodium
ascorb
mm
pmsf
vlp
purif
via
sucros
gradient
centrifug
ric
purif
via
protein
g
column
chromatographi
purif
protocol
conduct
describ
ntermin
extract
buffer
use
ph
instead
ph
experi
use
crude
leaf
extract
leaf
sampl
mg
extract
ml
ph
extract
buffer
contain
mm
trishcl
mm
nacl
mm
edta
triton
mm
sodium
ascorb
mm
pmsf
gfp
sampl
total
protein
extract
homogen
leaf
sampl
mg
ml
sd
sampl
buffer
mm
trishcl
ph
sd
glycerol
bromophenol
blue
follow
extract
acid
precipit
sampl
conduct
ad
n
phosphor
acid
final
acid
volum
solubl
leaf
extract
ph
acidprecipit
sampl
neutral
tri
base
five
minut
incub
acid
centrifug
min
supernat
acidprecipit
sampl
collect
analysi
sampl
crude
purifi
vlp
ric
mix
sd
sampl
buffer
final
concentr
mm
trishcl
ph
sd
glycerol
bromophenol
blue
ml
load
run
polyacrylamid
gel
biorad
reduc
condit
mm
dtt
ad
sampl
boil
min
prior
load
polyacrylamid
gel
either
transfer
pvdf
membran
stain
coomassi
stain
biorad
hercul
ca
usa
follow
manufactur
instruct
gfp
gel
imag
uv
light
fluoresc
band
intens
quantifi
use
imagej
softwar
use
endogen
plant
protein
band
intens
intern
load
control
detect
protein
transfer
membran
block
dri
milk
pbst
pb
overnight
c
wash
pbst
wash
min
probe
specifi
antibodi
cric
sampl
detect
goat
antihuman
igg
southern
biotech
birmingham
al
usa
antibodi
conjug
horseradish
peroxid
hrp
southern
biotech
birmingham
al
usa
nric
sampl
detect
mous
antihuman
igg
fconli
antibodi
conjug
hrp
southern
biotech
vlp
sampl
detect
polyclon
rabbit
antizika
e
follow
goat
antirabbit
hrp
conjug
bound
antibodi
detect
pierc
ecl
western
blot
substrat
accord
manufactur
instruct
thermo
fisher
scientif
waltham
usa
pool
sampl
sucros
gradient
purifi
vlp
dialyz
pb
ph
incub
mesh
grid
coat
formvar
incub
sampl
wash
twice
deioniz
water
neg
stain
aqueou
uranyl
acet
transmiss
electron
microscopi
perform
phillip
microscop
imag
acquir
gatan
model
ccd
camera
group
n
femal
balbc
mice
week
old
immun
subcutan
follow
construct
purifi
plantexpress
ntermin
ric
nric
ctermin
ric
cric
vlp
antigen
either
deliv
alon
variou
combin
ric
vlp
mix
group
given
antigen
mix
imject
alum
thermo
fisher
scientif
waltham
usa
prior
immun
howev
two
group
alon
cric
given
alum
order
test
effect
alum
respons
elicit
deliv
vaccin
antigen
group
total
dose
antigen
set
deliv
equival
lg
quantif
immun
proport
fulli
assembl
ie
antigen
determin
sdspage
western
blot
use
antibodi
detect
cleavag
product
imagej
softwar
use
quantifi
percentag
antigen
protein
concentr
determin
spectroscopi
sdspage
use
calcul
amount
need
deliv
mg
dose
given
day
serum
collect
done
describ
submandibular
bleed
day
anim
handl
accord
anim
welfar
act
arizona
state
univers
iacuc
bind
measur
previous
describ
mous
zika
e
specif
antibodi
titer
measur
elisa
zika
solubl
ectodomain
e
zse
protein
amino
acid
tag
produc
agroinfiltr
deliveri
express
vector
leav
n
benthamiana
purifi
metal
affin
chromatographi
zse
crude
plant
extract
neg
control
bound
highbind
polystyren
plate
corn
inc
corn
ny
usa
plate
block
nonfat
dri
milk
pbst
pb
well
wash
pbst
mous
serum
sampl
preadsorb
remov
plantreact
antibodi
incub
pvdf
membran
coat
crude
plant
extract
h
dilut
mous
sera
bleed
ad
plate
incub
h
mous
antibodi
detect
incub
polyclon
goat
antimous
igghorseradish
peroxidas
conjug
sigmaaldrich
st
loui
mo
usa
plate
develop
tmb
substrat
thermo
fisher
scientif
waltham
usa
absorb
read
nm
endpoint
titer
taken
reciproc
lowest
dilut
produc
read
twice
background
statist
analysi
variou
vaccin
treatment
done
nonparametr
mannwhitney
test
use
graphpad
prism
softwar
epitop
bind
ng
dengu
consensu
envelop
domain
iii
tag
epitop
bound
highbind
polystyren
plate
corn
inc
corn
ny
usa
plate
block
nonfat
dri
milk
pbst
pb
wash
pbst
variou
concentr
either
zehl
antibodi
ad
plate
plate
incub
h
wash
thrice
pbst
detect
goat
anti
human
igg
kappa
hrp
conjug
southern
biotech
birmingham
al
usa
plate
develop
tmb
substrat
thermo
fisher
scientif
waltham
usa
absorb
read
nm
prnt
assay
perform
describ
previous
briefli
mous
sera
group
pool
heat
inactiv
dilut
optimem
media
invitrogen
zikv
atcc
dilut
plaqueform
unit
pfu
per
ml
mix
equal
volum
dilut
mous
sera
optimem
media
viru
control
incub
hr
virusserum
mixtur
transfer
plate
contain
confluent
monolay
vero
cell
atcc
virusserumcontain
medium
remov
incub
hr
cell
overlaid
agaros
dmem
medium
fb
invitrogen
ca
plate
incub
hr
vero
cell
fix
paraformaldehyd
pfa
milliporesigma
stain
crystal
violet
visual
zikv
plaqu
plaqu
well
count
percent
neutral
calcul
number
zikv
plaqu
per
well
viru
control
well
number
zikv
plaqu
per
well
dilut
serum
number
zikv
plaqu
per
well
viru
control
well
neutral
antibodi
titer
express
reciproc
highest
dilut
serum
neutral
zikv
myriad
igg
fusion
creat
differ
antibodi
fusion
partner
linkag
result
variabl
express
stabil
improv
versatil
ric
platform
antigen
fusion
nterminu
ric
construct
nric
evalu
gfp
fuse
either
nterminu
cterminu
human
heavi
chain
contain
epitop
tag
allow
immun
complex
format
result
construct
fig
place
replic
geminivir
plant
express
vector
agroinfiltr
n
benthamiana
leav
monitor
gfp
express
gfp
nric
produc
bright
green
fluoresc
gfp
cric
produc
lower
level
gfp
fluoresc
fig
control
immun
complex
format
gfp
ric
also
express
absenc
light
chain
need
effici
epitop
tag
bind
epitop
tag
remov
without
light
chain
nric
construct
clearli
outperform
cric
construct
indic
gfp
ntermin
fusion
like
stabl
regardless
immun
complex
format
light
chain
assembl
fig
furthermor
nric
cric
perform
better
construct
lack
epitop
tag
suggest
immun
complex
format
may
play
role
stabil
fusion
fig
evalu
express
assembl
cric
nric
total
protein
extract
agroinfiltr
leaf
spot
analyz
nonreduc
sdspage
nric
cric
produc
high
level
fluoresc
band
expect
size
kda
fulli
assembl
gfp
ric
fig
howev
nric
construct
produc
total
yield
cric
construct
fig
p
without
epitop
tag
total
express
reduc
fig
e
taken
togeth
data
indic
ntermin
antigen
fusion
strong
potenti
gener
improv
ric
construct
evalu
nric
use
model
antigen
investig
nric
contain
sinc
show
ade
dengu
infect
also
contain
sever
neutral
epitop
monoclon
antibodi
promis
vaccin
candid
nric
cric
contain
amino
acid
zikv
e
protein
creat
similar
manner
gfp
ric
construct
construct
transient
express
transgen
plant
silenc
xylosyltransferas
fucosyltransferas
humanlik
nlink
glycosyl
pattern
enhanc
vivo
bind
antibodi
fc
receptor
acid
precipit
use
partial
purifi
antibodi
remov
plant
contamin
could
otherwis
imped
purif
analysi
crude
leaf
extract
show
cric
nric
stabl
acid
precipit
fig
use
elisa
design
detect
fulli
assembl
igg
molecul
nric
found
produc
lg
igg
per
gram
leaf
fresh
weight
lgg
lfw
wherea
cric
produc
lgg
lfw
fig
stain
sdspage
gel
western
blot
show
purifi
cric
nric
sampl
display
expect
molecular
mass
nonreduc
condit
kda
reduc
condit
kda
kda
band
fig
furthermor
ric
highli
pure
littl
sign
degrad
contamin
fig
determin
fusion
near
variabl
domain
would
inhibit
abil
construct
form
immun
complex
elisa
perform
measur
epitop
bind
sinc
ric
would
expect
bind
epitop
tag
nearbi
ric
molecul
thu
interfer
elisa
otherwis
ident
nric
construct
lack
epitop
tag
creat
bound
immobil
epitop
tag
strongli
unfus
untag
antibodi
indic
ntermin
fusion
notabl
inhibit
epitop
bind
fig
consist
format
immun
complex
cric
nric
found
bind
complement
receptor
substanti
uncomplex
antibodi
fig
previous
found
synergist
enhanc
immunogen
ric
codeliv
hepat
b
core
antigen
hbc
vlp
gener
hbc
vlp
carri
codeliveri
nric
cric
antigen
flank
flexibl
linker
insert
second
two
test
whether
crude
leaf
extract
cric
nric
construct
stabl
upon
acidprecipit
n
phosphor
acid
ad
final
acid
volum
total
solubl
extract
follow
fiveminut
incub
sampl
neutral
tri
base
sampl
extract
without
acidprecipit
includ
comparison
sampl
mix
nonreduc
sampl
buffer
load
polyacrylamid
gel
western
blot
probe
hrplabel
goat
antihuman
igg
h
l
abbrevi
minu
refer
leaf
extract
without
acid
precipit
plu
refer
leaf
extract
acidprecipit
b
leav
infiltr
cric
nric
express
vector
crude
leaf
extract
analyz
igg
product
elisa
dpi
column
repres
mean
standard
deviat
independ
infiltr
leaf
sampl
p
valu
measur
student
ttest
tandemlylink
hbc
gene
copi
insert
region
apex
ahel
hbc
spike
upon
dimer
two
hbc
spike
one
hbc
copi
would
contain
antigen
therebi
potenti
increas
stabil
vlp
altern
ctermin
fuse
hbc
monom
beydv
express
vector
contain
hbc
heterodim
vlp
construct
ctermin
hbc
fusion
agroinfiltr
n
benthamiana
plant
confirm
format
vlp
agroinfiltr
leaf
sampl
harvest
dpi
clarifi
leaf
extract
analyz
sucros
gradient
centrifug
sdspage
western
blot
vlp
band
around
expect
size
kda
found
predomin
sucros
layer
consist
vlp
format
fig
electron
microscopi
use
confirm
presenc
fulli
form
vlp
fig
balbc
mice
per
group
immun
subcutan
mg
deliv
nric
cric
hbche
vlp
hbc
vlp
either
alon
variou
combin
ric
vlp
mix
second
dose
ric
vlp
group
reach
high
titer
best
group
achiev
endpoint
titer
excess
fig
combin
group
ric
vlp
signific
increas
igg
antibodi
titer
compar
group
contain
vlp
ric
p
signific
differ
cric
nric
p
signific
differ
present
hbche
spike
ctermin
fuse
hbc
p
small
statist
insignific
decreas
titer
group
lack
alum
p
trend
continu
third
dose
codeliveri
either
cric
nric
vlp
produc
increas
antibodi
titer
high
titer
produc
ric
vlp
alon
approxim
less
p
fig
result
prnt
analysi
show
sera
mous
group
immun
antigen
exhibit
neutral
activ
zikv
p
compar
sera
group
versu
pb
sera
fig
furthermor
group
except
hbche
group
reach
neutral
titer
fig
addit
sera
ric
group
perform
better
vlp
group
p
fig
vlp
ric
combin
group
best
neutral
p
sera
compar
sera
fig
vlp
group
lack
alum
perform
significantli
better
group
contain
alum
p
hbche
sera
versu
hbche
alum
sera
fig
taken
togeth
result
show
robust
titer
zikv
neutral
achiev
either
nric
cric
vlp
ric
deliv
togeth
potent
either
alon
reemerg
zika
infect
remain
signific
health
threat
worldwid
necessit
safe
afford
effect
vaccin
strategi
especi
protect
pregnant
women
fetus
subunit
vaccin
target
promis
candid
highli
conserv
among
zikv
strain
antibodi
shown
highli
potent
neutral
divers
zikv
strain
african
asian
american
lineag
howev
weak
immunogen
must
overcom
antigen
incorpor
immun
complex
proven
method
strongli
enhanc
bcell
tcell
respons
absenc
adjuv
howev
one
drawback
tradit
ric
platform
antigen
fusion
occur
nterminu
antigen
cterminu
ric
antibodi
method
fusion
feasibl
antigen
especi
inaccess
nterminu
modifi
ric
platform
permit
antigen
fusion
cterminu
antigen
nterminu
antibodi
drawback
overcom
demonstr
modifi
nric
platform
near
ident
immun
properti
tradit
cric
also
increas
express
solubl
use
two
differ
fusion
protein
maintain
similar
level
stabil
upon
exposur
acid
condit
fig
observ
effect
varieti
antigen
data
present
elsewher
suggest
least
ric
platform
nric
configur
may
inher
stabl
find
extend
versatil
ric
platform
accommod
wider
varieti
antigen
plantproduc
subunit
vaccin
potenti
overcom
safeti
cost
concern
associ
zikv
vaccin
candid
plant
express
system
highli
scalabl
contain
anim
pathogen
also
avoid
mani
cost
tradit
express
system
expens
bioreactor
therebi
allow
cheaper
product
biolog
product
previous
describ
robust
plant
express
system
base
bean
yellow
dwarf
viru
permit
high
level
protein
product
n
benthamiana
recent
studi
plastidengin
tobacco
plant
demonstr
viabil
plantbas
protein
product
field
set
result
show
fieldgrown
tobacco
express
recombin
protein
capabl
achiev
order
magnitud
reduct
cost
compar
tradit
cell
cultur
method
addit
glycosyl
state
antibodi
therapeut
crucial
function
plant
uniqu
suit
produc
ric
vaccin
antibodi
made
glycoengin
plant
demonstr
improv
fccri
fccriiia
bind
lead
improv
antibodydepend
cellular
cytotox
complementdepend
cytotox
overal
increas
potenc
compar
commerci
antibodi
made
mammalian
cell
find
fulli
assembl
highli
express
fig
ric
made
glycoengin
plant
interact
strongli
complement
fig
elicit
potent
antibodi
respons
neutral
zikv
fig
antigen
fusion
rel
small
nterminu
discern
effect
antibodi
bind
fig
observ
larger
antigen
incorpor
nric
mous
total
antibodi
titer
balbc
mice
per
group
immun
subcutan
nric
cric
vlp
either
alon
variou
combin
ric
vlp
mix
two
group
alon
given
alum
adjuv
order
test
effect
adjuv
antibodi
titer
elicit
experiment
group
except
pb
control
group
dose
deliv
mg
total
blood
sampl
collect
second
dose
b
third
dose
analyz
antibodi
endpoint
titer
elisa
yaxi
show
geometr
mean
titer
gmt
pb
control
group
signal
background
lowest
dilut
test
therefor
shown
improv
readabl
nonparametr
oneway
anova
use
evalu
signific
group
indic
may
inhibit
antibodi
bind
data
present
elsewher
reduc
epitop
bind
could
impair
immun
complex
format
howev
smaller
immun
complex
may
fact
desir
larg
immun
complex
poorli
solubl
larg
particul
size
nm
effici
enter
lymphat
system
inde
hexamers
igg
found
potent
activ
complement
larger
oligom
less
effect
studi
accur
control
assess
relationship
ric
size
immunogen
need
address
question
hepadnavir
hepat
b
core
hbc
antigen
protein
wellstudi
vlp
model
selfassembl
particl
noninfecti
yet
form
highli
immunogen
platform
display
foreign
antigen
upon
selfassembl
surfac
vlp
contain
array
dimer
ahel
spike
use
insert
site
foreign
antigen
howev
base
size
insert
antigen
direct
fusion
antigen
hbc
spike
might
destabil
vlp
due
antigen
steric
hinder
would
prevent
appropri
vlp
assembl
insert
antigen
one
two
tandemlylink
hbc
gene
copi
possibl
lessen
problem
destabil
lead
increas
capac
hbc
vlp
display
antigen
addit
hbc
vlp
effici
produc
number
express
system
includ
plant
studi
found
display
either
heterodimer
hbc
ctermin
fuse
hbc
monom
produc
fulli
form
highli
immunogen
vlp
nearli
indistinguish
immunogen
properti
fig
ctermin
hbc
fusion
vlp
show
slightli
differ
mean
neutral
activ
differ
statist
signific
p
fig
alum
use
success
varieti
vlpbase
vaccin
alum
may
destabil
conform
structur
epitop
interestingli
addit
alum
vlp
neglig
effect
antibodi
titer
howev
zikv
neutral
stronger
without
alum
p
fig
may
suggest
alum
interfer
present
neutral
epitop
vlp
antigen
may
also
perform
differ
depend
whether
present
ric
vlp
import
epitop
may
obscur
improperli
fold
depend
interact
antigen
ric
vlp
fusion
middl
east
respiratori
syndrom
coronaviru
spike
protein
igg
fc
interf
protein
fold
lead
reduc
immunogen
zikv
neutral
pool
mous
sera
termin
bleed
sampl
dilut
ratio
b
incub
zikv
prior
infect
vero
cell
prnt
assay
assess
zikvspecif
neutral
antibodi
sera
mean
neutral
sd
three
independ
experi
technic
triplic
sampl
present
indic
p
valu
respect
comparison
oneway
anova
sera
pbsinject
group
mous
group
directli
error
bar
indic
mous
group
compar
previou
studi
ric
display
segment
human
papillomaviru
antigen
ric
describ
studi
significantli
solubl
data
shown
differ
aggreg
properti
may
contribut
differ
immunogen
similarli
vlp
assembl
heterogen
process
may
affect
electrostat
steric
properti
antigen
insert
despit
potenti
factor
other
nonetheless
observ
strong
immunogen
plantmad
ric
vlp
target
wide
varieti
antigen
previous
demonstr
synergist
enhanc
antibodi
respons
upon
codeliveri
ric
vlp
display
hpv
deliveri
either
ric
vlp
result
high
antibodi
titer
codeliveri
ric
vlp
result
higher
antibodi
titer
either
ric
vlp
alon
agreement
result
find
strong
synergist
enhanc
antibodi
titer
ric
vlp
deliv
togeth
fig
p
correl
improv
zikv
neutral
fig
base
observ
ric
vlp
combin
shown
enhanc
neutral
antibodi
titer
describ
hpv
influenza
data
present
elsewher
indic
enhanc
antigenspecif
ric
activ
complement
elicit
fcmediat
effector
function
hbc
vlp
contain
strong
tcell
epitop
potent
activ
macrophag
may
stimul
tlr
due
encapsid
nucleic
acid
therefor
provid
ric
vlp
simultan
may
stimul
arm
immun
system
produc
multipl
rather
addit
effect
work
need
determin
synergi
requir
simultan
codeliveri
vlp
ric
similar
effect
could
achiev
prime
either
ric
vlp
follow
heterolog
boost
conclus
alter
antigen
fusion
site
creat
ric
accommod
wider
rang
antigen
result
show
incorpor
nric
cric
vlp
effici
assembl
express
high
level
plant
ric
vlp
strongli
enhanc
immunogen
effect
even
potent
codeliv
platform
reach
high
antibodi
titer
neutral
zikv
two
dose
without
adjuv
anticip
platform
use
creat
cheap
effect
vaccin
zikv
well
broad
applic
develop
vaccin
diseas
author
declar
follow
financi
interestsperson
relationship
may
consid
potenti
compet
interest
qiang
chen
employe
greenbio
az
conflict
interest
publish
manuscript
hugh
mason
unpaid
advisor
fruitvaccin
inc
conflict
interest
publish
manuscript
